Gritstone bio, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
24 juin 2024 18h52 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Gritstone bio, Inc....
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Enphase, Fat Brands, Scotts, and Gritstone and Encourages Investors to Contact the Firm
21 juin 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
19 juin 2024 12h30 HE
|
Schall Law
GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Scotts, and Gritstone and Encourages Investors to Contact the Firm
17 juin 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
GRITSTONE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gritstone bio, Inc. and Encourages Investors to Contact the Firm
11 juin 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
01 avr. 2024 16h01 HE
|
Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 janv. 2022 07h00 HE
|
Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...